• the revised version of ''Asb2 regulates the activity of SCF E3 ubiquitin ligases by antagonizing CAND1-mediated exchange of F-box proteins,'' submitted to *Molecular Cell* on September 29, 2014; hereafter referred to as the ''revised *Molecular Cell* manuscript

• grant application CA189216–01 submitted to the National Cancer Institute (NCI), NIH; hereafter referred to as the ''original NCI grant application''

• grant application CA189216–01A1 submitted to NCI, NIH; hereafter referred to as the ''revised NCI grant application''

ORI found that Respondent knowingly falsified and/or fabricated Western blot gel images by duplication, reuse and relabeling, and/or alteration through contrast, rotation, and/or scale of the images.

Specifically, Respondent included falsified images in all of the figures (Figures 1–6 and S1–5) in the original *Molecular Cell* manuscript, all of the figures (Figures 1–6 and S1–7) in the revised

Molecular Cell manuscript, Figures 2–4, 9, and 11 in the original NCI grant application, and Figures 3–5, 10, and 11 in the revised NCI grant application.

Dr. Kang has entered into a Voluntary Settlement Agreement (Agreement) and has voluntarily agreed for a period of three (3) years, beginning on December 23, 2014:

(1) To have his research supervised; Respondent agreed to ensure that prior to the submission of an application for U.S. Public Health Service (PHS) support for a research project on which the Respondent's participation is proposed and prior to Respondent's participation in any capacity on PHS-supported research, the institution employing him must submit a plan for supervision of his duties to ORI for approval; the plan for supervision must be designed to ensure the scientific integrity of Respondent's research contribution; Respondent agreed that he will not participate in any PHS-supported research until such a supervision plan is submitted to and approved by ORI; Respondent agreed to maintain responsibility for compliance with the agreed upon plan for supervision;

(2) that any institution employing him must submit, in conjunction with each application for PHS funds, or report, manuscript, or abstract involving PHS-supported research in which Respondent is involved, a certification to ORI that the data provided by Respondent are based on actual experiments or are otherwise legitimately derived and that the data, procedures, and methodology are accurately reported in the application, report, manuscript, or abstract; and

(3) to exclude himself voluntarily from serving in any advisory capacity to PHS including, but not limited to, service on any PHS advisory committee, board, and/or peer review committee, or as a consultant.

FOR FURTHER INFORMATION CONTACT: Acting Director, Office of Research Integrity, 1101 Wootton Parkway, Suite 750, Rockville, MD 20852, (240) 453–8200.

Donald Wright,

Acting Director, Office of Research Integrity.

[FR Doc. 2015–00802 Filed 1–16–15; 8:45 am]

BILLING CODE 4150–31–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Office of the Secretary; Office of Medicare Hearings and Appeals; Statement of Organization, Functions, and Delegations of Authority

Part A, Office of the Secretary, Statement of Organization, Functions, and Delegations of Authority for the Department of Health and Human Services, is being amended at Chapter AK, Office of Medicare Hearings and Appeals (OMHA), as last amended at 70 FR 36386–36387, dated June 23, 2005, and most recently at 76 FR 19995 (Apr. 11, 2011) as follows:

I. Under Section AK.10, Organization, delete the bullets and sub-bullets after the phrase, ''OMHA consists of the following components,'' and replace with the following:

• Medicare Hearings and Appeals Chief Judge's Office (CJO) (Headquarters Office)

— Office of Operations

— Office of Programs

• Medicare Hearings and Appeals Field Offices

II. Under Section AK.20, Functions, Paragraph B, replace ''Medicare Hearings and Appeals Field Offices (AKB1–4)'' with ''Medicare Hearings and Appeals Field Offices.''

III. Under Section AK.20, Functions, Paragraph B, ''Medicare Hearings and Appeals Field Offices,'' replace all references to the ''Managing Administrative Law Judge (MALJ)'' with ''Associate Chief Administrative Law Judge (ACALJ).''

Dated: January 13, 2015.

E.J. Holland, Jr.,

Assistant Secretary for Administration (ASA).

[FR Doc. 2015–00743 Filed 1–16–15; 8:45 am]

BILLING CODE 4150–24–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Medicare & Medicaid Services

[CMS–3303–FN]

Medicare and Medicaid Programs; Continued Approval of the Accreditation Commission for Health Care, Inc.; Home Health Agency Accreditation Program

AGENCY: Centers for Medicare and Medicaid Services, HHS.

ACTION: Final notice.

SUMMARY: This final notice announces our decision to approve the Accreditation Commission for Health Care, Inc., (ACHC) for continued recognition as a national accrediting organization for home health agencies (HHAs) that wish to participate in the Medicare or Medicaid programs. An HHA that participates in Medicaid must also meet the Medicare conditions for participation (CoPs) as required under 42 CFR 488.6(b).

DATES: This final notice is effective February 24, 2015 through February 24, 2021.

FOR FURTHER INFORMATION CONTACT: Cindy Melanson, (410) 786–0310, or Patricia Chmielewski, (410) 786–6899.

SUPPLEMENTARY INFORMATION:

I. Background

A healthcare provider may enter into an agreement with Medicare to participate in the program as a HHA provided certain requirements are met. Sections 1861(o) and 1891 of the Social Security Act (the Act), establish distinct criteria for facilities seeking designation as a HHA. Regulations concerning Medicare provider agreements in general are at 42 CFR part 489 and those pertaining to the survey and certification for Medicare participation of providers and certain types of suppliers are at part 488. The regulations at part 484 specify the specific conditions that a provider must meet to participate in the Medicare program as an HHA.

Generally, to enter into a Medicare provider agreement, a facility must first be certified as complying with the conditions set forth in part 484 and recommended to us for participation by